Global In Vitro Lung Model Market – Industry Trends and Forecast to 2030

Global In Vitro Lung Model Market, By Type (2D, 3D), Application (Drug Screening, Toxicology, 3D Model Development, Basic Research, Physiologic Research, Stem Cell Research, Regenerative Medicine) – Industry Trends and Forecast to 2030.

In Vitro Lung Model Market Analysis and Size

The increasing research on lung diseases is expected to provide growth potential for the market at the global level. The cases of lung cancer, asthma, and COPD have been increasing globally at a major speed. The significant advancements and the huge development of new 3D in vitro models have also pushed the market's growth. The huge development of varied new therapeutics for the treatment of increasing lung diseases requires many advanced organ models that closely recapitulate the human lung's complexity.  

Data Bridge Market Research analyses that the in vitro lung model market is expected to reach USD 1025.71 million by 2030 from USD 296.13 million in 2022 with a CAGR of 16.8% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

In Vitro Lung Model Market Scope and Segmentation

Market Definition

Lung In vitro models are the cell models that represent diseased or normal lung physiology. Animal testing is still the most widespread model which is used to study numerous diseases but in order to decrease animal experimentation, a high need for realistic and well-accepted in vitro substitutes has arisen. In vitro lung model can be set by culturing macrophages, epithelial cells, and dendritic cells favourable for the culture medium.

In Vitro Lung Model Market Dynamics

Drivers

• Increased Collaborations and Partnerships

The partnerships, recent developments, mergers and acquisitions are fuelling the market growth For instance, Lonza Group AG and Agilent Technologies in December 2021, entered into a strategic collaboration to incorporate new analytical technologies with Lonza’s Cocoon Platform. The aim was to develop and add current and new analytical technologies into patient-scale cell therapy manufacturing workflows with the Cocoon Platform. It will bring both companies a step ahead to their commitment to highly developing sustainable technologies and solutions increasing access to life-saving cell-based therapies for various lung diseases. Furthermore, BICO subsidiaries CELLINK, MatTek, and Visikol in September 2021 entered into the launch of a collaboration along with the expertise of the three companies to create a contract research organization with comprehensive bioprinting services. The partnership with the BICO groups’ commit to its Bio Convergence agenda by identifying synergies in the bioprinting business area to provide customers solutions drifting toward the future of health.

Opportunities

• Increased Demand of 2-D Cell Models

There has been an immense growth of 2-D cell models in the past few years. There has been a constant effort to develop in vitro lung models to understand and study the mechanism of numerous lung diseases, such as idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF). The cases of these numerous diseases lead to the huge development 2-D lung model to understand the pathogenesis of the microbes. For instance, the Centre for Disease Control and Prevention (CDC) in 2021 stated that in 2020, 21,030,479 adult cases and 4,226,659 children were reported worldwide who suffer from asthma. Therefore, increasing cases of these diseases are increasing the development of a 2-D lung model thus driving the growth of the segment.

Restraints/Challenges

• Lack of Expert Professionals

Lack of trained and skilled healthcare professionals and technicians led to the restriction of the market growth. Many trained professionals are required to perform this diagnostic model, which is often not available in the lower economic countries, which hampers the market growth.

This in vitro lung model market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the in vitro lung model market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on In Vitro Lung Model Market

The COVID-19 pandemic had a significant impact on the in-vitro lung model market. According to an article titled, "In Vitro Lung Models and Their Application to Study SARS-CoV-2 Pathogenesis and Disease" which was published in April 2021 stated that the pandemic had a major impact on the in-vitro lung model as the spread of the virus led to the development of in-vitro lung model to study the pathogenesis of this virus. At first, the growth of this market was hindered by strict lockdowns but with in the post pandemic era, the surge in clinical studies and understanding of the pathophysiology of this virus, the studied market observed major growth.

Recent Developments

• In 2022, Merit Medical Systems launched TEMNO Elite Soft Tissue Biopsy System which is for use in numerous soft tissue locations such as lung, liver, lymph nodes, kidney, and other soft tissue suspect lesions.
• In 2022, AlveoliX partnered with InSCREENeX. Through this partnership, InSCREENeX’s cutting-edge CI-SCREEN methodology with AlveoliX’s patented organ-on-chip technology will launch a new immortalized alveolar cell line, that is specially tuned for on-chip applications

In Vitro Lung Model Market Scope

The in vitro lung model market is segmented on the basis of type, application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• 2D
• 3D

Application

• Drug Screening
•  Toxicology
• 3D Model Development
• Basic Research
• Physiologic Research
• Stem Cell Research
• Regenerative Medicine

In Vitro Lung Model Market Regional Analysis/Insights

The in vitro lung model market is analyzed and market size insights and trends are provided by type, application as referenced above.

The countries covered in the in vitro lung model market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the in vitro lung model market due to the extensive presence of key market players, increase in research funding from numerous organizations, well-established health care infrastructure and surge in R&D activities by several pharmaceutical and biotechnology companies.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the increasing focus of several major players on the market in these countries, along with increasing awareness, enlarged government initiatives, and emerging health care infrastructure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The in vitro lung model market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for in vitro lung model market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the in vitro lung model market. The data is available for historic period 2011-2020.

Competitive Landscape and Global In Vitro Lung Model Market Share Analysis

The in vitro lung model market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to in vitro lung model market.

Some of the major players operating in the in vitro lung model market are:

• Epithelix (Switzerland)
• MATTEK.(U.S.)
• Lonza (Switzerland)
• ATCC (U.S.)
• InSphero (U.S.)
• Emulate (U.S.)
• AlveoliX AG (Switzerland)
• Mimetas US Inc (Netherlands)
• TissUse GmbH (Germany)
• Konica Minolta Business Solutions India Private Limited. (Japan)
• Hologic, Inc. (U.S.)
• Brainlab AG (Germany)
• Varian Medical Systems, Inc (U.K.)
• McKesson Corporation (U.S.)
• MICA Information Systems, Inc. (U.S.)
• Olympus Corporation (India)